Lung cancer (CP) is one of the most frequently diagnosed cancers worldwide. In Spain, the estimated incidence of new cases of CP for 2019 was 29,503 cases. CP continues to be the leading cause of cancer death in Spain in both sexes, with an overall five-year survival of 13%, which decreases to 1% in the metastatic stage. Non-small cell lung cancer (PCNM) accounts for approximately 80% - 90% of all CPs and is classified according to histology into adenocarcinoma (≈ 40%), large cell carcinoma (15%), and cell carcinoma. squamous or epidermoid cells (≈ 25-30%) .
Metastatic non-microcytic lung cancer; Osimertinib; Targeted therapy; Health results
Programa d'Harmonització Farmacoterapèutica. Tractament del CPNM EFGR i T790M positiu amb osimertinib: informe d'avaluació de resultats. Barcelona: Servei Català de la Salut; 2021.
Use this identifier for quote and/or link this documenthttps://hdl.handle.net/11351/6351
This item appears in following collections
The following license files are associated with this item: